^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:FoundationOne®PGx
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Foundation MedicineType:
Research Use Only
FoundationOne®PGx is designed and customized to detect genetic variations in the following nine (9) genes associated with actionable oncology drug metabolism that are included in either the FDA's pharmacogenetic associations for which the data support therapeutic management recommendations list or other PGx clinical implementation guidelines
Gene:
CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9), CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6), DPYD (Dihydropyrimidine Dehydrogenase), G6PD (Glucose-6-Phosphate Dehydrogenase), NUDT15 (Nudix Hydrolase 15), TPMT (Thiopurine S-Methyltransferase)
See More ...
CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9), CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6), DPYD (Dihydropyrimidine Dehydrogenase), G6PD (Glucose-6-Phosphate Dehydrogenase), NUDT15 (Nudix Hydrolase 15), TPMT (Thiopurine S-Methyltransferase), UGT1A1 (UDP glucuronosyltransferase family 1 member A1), UGT1A4 (UDP Glucuronosyltransferase Family 1 Member A4)
Method:
Targeted pharmacogenomic genotyping